Welcome to the 3rd Next Generation RNA Therapeutics Summit:
Pioneering the Next Breakthrough in Durable & Potent RNA Therapeutics for Patients
The field of next generation RNA therapeutics continues to progress towards clinical translation, with enormous investments and collaborations, such as Orbital Therapeutics’ recent $270 million Series A financing.
The 3rd Next Generation RNA Therapeutics Summit returns to cover the depth and breadth of the next of generation RNAs, including circular RNA, self-amplifying RNA (saRNA) and beyond from discovery to clinic and towards scalable manufacturing, unlocking the huge therapeutic and commercial potential of this emerging class of modalities.
Join 120+ expert leaders in Discovery, R&D, Engineering, Preclinical Translation and CMC from the key stakeholders pioneering advances in RNA technologies and continue to fast-track these next generation therapies into the clinic, and towards patients faster.
A Snapshot of the 22+ World-Class Speaker Faculty:
Chief Scientific Officer
Co-Founder & Chief Scientific Officer
What To Expect
Enhance characterization, safety and potency to develop and manufacture effective self-amplifying RNA therapeutics for patients with input from Johnson & Johnson, Replicate Bioscience & Strand Therapeutics
Unlock the widespread potential of RNA therapeutics with improved sequence design, target selection and in vivo delivery with insights from Atomic AI & Sanofi
Overcome quality and scalability hurdles to increase clinical success of circular RNAs towards patients in need with input from Orbital Therapeutics & Laronde
Successfully develop first-in-class next generation RNA therapies with groundbreaking potential to treat “incurable” diseases with insights from NoctuRNA Therapeutics, Circio & Pfizer
Learn from diverse platforms to address shared hurdles, differentiate pipelines and enhance next generation RNA strategies towards regulatory approval with input from John Hopkins University, Rothwell Figg & Capstan Therapeutics